#### **SCHEDULE 4**

#### Consequential amendments

## **Amendment of the Human Medicines Regulations 2012**

- **2.**—(1) The Human Medicines Regulations 2012(1) are amended as follows.
- [F1(2) In regulation 173 (exemption for certain radiopharmaceuticals), for paragraph (d) substitute—
  - "(d) for administration—
    - (i) in England and Wales and Scotland in accordance with a licence issued under the Ionising Radiation (Medical Exposure) Regulations 2017;
    - (ii) in Northern Ireland in accordance with a licence issued under the Ionising Radiation (Medical Exposure) Regulations (Northern Ireland) 2018.".";]
  - [F2(3)] For regulation 240 (radioactive medicinal products), substitute—

# "Radioactive medicinal products

- **240.**—(1) Regulation 214(2) does not apply to—
  - (a) a radioactive substance, administration of which results in a medical exposure; or
  - (b) any other prescription only medicine if it is being administered in connection with a medical exposure,

## if Conditions A to E are met.

- (2) Condition A is that the prescription only medicine is administered by an operator acting in accordance with the procedures and protocols referred to—
  - (a) in England and Wales and Scotland, in regulation 6(1) and (4) of the Ionising Radiation (Medical Exposure) Regulations 2017 which apply to the exposure;
  - (b) in Northern Ireland, in regulation 6(1) and (4) of the Ionising Radiation (Medical Exposure) Regulations (Northern Ireland) 2018 which apply to the exposure.
  - (3) Condition B is that the medical exposure has been authorised by—
    - (a) an IRME practitioner; or
    - (b) where it is not practical for an IRME practitioner to authorise the exposure, an operator acting in accordance with written guidelines issued by an IRME practitioner.
  - (4) Condition C is that—
    - (a) in England and Wales and Scotland, the IRME practitioner mentioned in subparagraph (a) or (b) of paragraph (3) is the holder of a licence issued under the Ionising Radiation (Medical Exposure) Regulations 2017;
    - (b) in Northern Ireland, the IRME practitioner mentioned in sub-paragraph (a) or (b) of paragraph (3) is the holder of a licence issued under the Ionising Radiation (Medical Exposure) Regulations (Northern Ireland) 2018.
- (5) Condition D is that the prescription only medicine is not a product subject to special medical prescription.
- (6) Condition E is that, in the case of a prescription only medicine that is not a radioactive substance, it is specified in the protocols referred to in paragraph (2).

1

 $<sup>\</sup>textbf{(1)} \quad \text{S.I. 2012/1916 as amended by S.I. 2014/490; there are other amending instruments but none is relevant.}$ 

# (7) In this regulation—

"IRME practitioner" means—

- (a) in relation to a medical exposure in England and Wales and Scotland, a practitioner for the purposes of the Ionising Radiation (Medical Exposure) Regulations 2017;
- (b) in relation to a medical exposure in Northern Ireland, a practitioner for the purposes of the Ionising Radiation (Medical Exposure) Regulations (Northern Ireland) 2018;

"medical exposure" has the same meaning—

- (a) in England and Wales and Scotland as in the Ionising Radiation (Medical Exposure) Regulations 2017;
- (b) in Northern Ireland as in the Ionising Radiation (Medical Exposure) Regulations (Northern Ireland) 2018;

"radioactive substance" has the same meaning—

- (a) in England and Wales and Scotland as in the Ionising Radiation (Medical Exposure) Regulations 2017;
- (b) in Northern Ireland as in the Ionising Radiation (Medical Exposure) Regulations (Northern Ireland) 2018.".]

#### **Textual Amendments**

- F1 Sch. 4 para. 2(2) substituted (6.2.2018) by The Ionising Radiation (Medical Exposure) (Amendment) Regulations 2018 (S.I. 2018/121), regs. 1(2), 2(4)(b)(i)
- F2 Sch. 4 para. 2(3) substituted (6.2.2018) by The Ionising Radiation (Medical Exposure) (Amendment) Regulations 2018 (S.I. 2018/121), regs. 1(2), 2(4)(b)(ii)

## **Commencement Information**

II Sch. 4 para. 2 in force at 6.2.2018, see reg. 1

Changes to legislation:
There are currently no known outstanding effects for the The Ionising Radiation (Medical Exposure) Regulations 2017, Paragraph 2.